Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT03349710
- Phase
- PHASE3
- Status
- Completed
Conditions
- Squamous Cell Carcinoma of the Head and Neck
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — BIOLOGICALSpecified dose on specified day
- Cetuximab — DRUGSpecified dose on specified day
- Cisplatin — DRUGSpecified dose on specified day
- Radiotherapy — RADIATIONSpecified dose on specified day
Study Details
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin
Key Dates
- Start date
- Dec 15, 2017
- Status verified
- Aug 2021
- Primary completion
- Oct 14, 2019
- Completion
- Oct 14, 2019
Study Design
- Enrollment
- 74 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm ACohort 1
- Experimental: Arm BCohort 1
- Experimental: Arm CCohort 2
- Experimental: Arm DCohort 2
Primary Outcome Measure
Number of Participants With an Adverse Event (AE) [ Time Frame: 30 Days ]
Locations (21)
Find similar trials in Anniston, AL
By research site
Related Studies
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerPHASE1 · Recruiting · Emory University · Atlanta, Georgia
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2 · Recruiting · Simcha IL-18, Inc. · Scottsdale, Arizona
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Birmingham, Alabama